A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use.
See the abstract here
A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use.
See the abstract here
FY26 Budget Watch, Advocacy Results, and State-Level Progress As Congress ramps up work on the FY26 federal budget, advocates are focused on maintaining vital cancer programs and advancing state policies … Continued
This article was updated in May 2025 to reflect NCCN’s release of the 2025 Guidelines for Cervical Cancer Patients. OCRA is a proud sponsor of 2025 Cervical Cancer Updates. We … Continued
The Food and Drug Administration has granted accelerated approval to Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets), made by Verastem Oncology, making it the first FDA-approved treatment for patients with … Continued
Get email updates about research news, action alerts, and ways to join the fight.